An overview of paediatric leishmaniasis

Journal of Postgraduate Medicine

Volumn 49, Issue 1, 2003, Pages 31-38

  Kafetzis, Dimitris A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Amphotericin; Antimonials; Children; Liposomal amphotericin; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; DNA VACCINE; GAMMA INTERFERON; KETOCONAZOLE; LEISHMANIA VACCINE; LIVE VACCINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE MESYLATE; RECOMBINANT DNA; STIBOGLUCONATE SODIUM;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILL; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROLYTE DISTURBANCE; ENDEMIC DISEASE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEPATOMEGALY; HUMAN; HUMORAL IMMUNITY; HYPERGAMMAGLOBULINEMIA; HYPOTENSION; IMMUNOCOMPETENCE; INJECTION PAIN; INSECT BITE; JOINT STIFFNESS; KIDNEY FAILURE; LEISHMANIA; LEUKOPENIA; LIVER DYSFUNCTION; LONG QT SYNDROME; LYMPHADENOPATHY; MALNUTRITION; MYALGIA; NAUSEA; NEPHROTOXICITY; PALLOR; PANCREATITIS; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; PARASITE VIRULENCE; PARASITOSIS; PNEUMONIA; PSYCHODIDAE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SPLENOMEGALY; THROMBOCYTOPENIA; VISCERAL LEISHMANIASIS; VOMITING; WEIGHT REDUCTION;

EID: 0037869141     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.930     Document Type: Review

References (56)

1. Peter CM. Leishmaniasis. In: Behrman RE, Kliegman RM, Jenson HB, editors. Nelson Textbook of Pediatrics. 16th edn. Philadelphia WB Saunders; 2000.
2. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
3. Murray W. Leishmaniasis. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th edn. Philadelphia: WB Saunders; 1998.
4. Committee on Infectious Disease, American Academy of Paediatrics: 1997 Red Book: Report of the Committee on Infectious Diseases, 24th edn. pp 321-3.
5. Gramiccia M, Gradoni L, Pozio E. Leishmania. infantum sensu lato as an agent of cutaneous leishmaniasis in Abruzzi region (Italy). Trans R Soc Trop Med Hyg 1987;81:235-7.
6. Zeledon R, Hidalgo H, Viquez A, Urbina A. Atypical cutaneous leishmaniasis in a semiarid region of northwest Costa Rica. Trans R Soc Trop Med Hyg 1989;83:786.
7. Ponce C, Ponce E, Morrison A, Cruz A, Kreutzer R, McMahon-Pratt D, et al. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet 1991;337:67-70.
8. Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 2000;4:158-77.
9. Vecsei AK, Kastner U, Trebo M, Kornmuller R, Picher O, Schratzberger-Vecsei E, et al. Paediatric visceral leishmaniasis in Austria: diagnostic difficulties in a non-endemic area. Wien Klin Wochenschr 2001;113:102-6.
10. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001;80:54-73.
11. Schaefer KU, Kurtzhals JA, Sherwood JA, Githure JI, Kager PA, Muller AS. Epidemiology and clinical manifestations of visceral and cutaneous leishmaniasis in Baringo, District, Rift Valley, Kenya. A literature review. Trop Geogr Med 1994;46:129-33.
12. Pearson RD, Lareau SM, Jeronimo SM. Leishmaniasis at the End of the Millennium. Curr Infect Dis Rep 1999 Dec; 1:448-52.
13. Totan M, Dagdemir A, Muslu A, Albayrak D. Visceral childhood leishmaniasis in Turkey. Acta Paediatr 2002;91:62-4.
14. Haidar NA, Diab ABL, El-Sheikh AM. Visceral leishmaniasis in children in the Yemen. Saudi Med J 2001;22:516-9.
15. Minodier P, Piarroux R, Garnier JM, Unal D, Perrimond H, Dumon H. Paediatric visceral leishmaniasis in southern France. Pediatr Infect Dis J 1998;17:701-4
16. Enserink M. Infectious diseases. Has leishmaniasis become endemic in the United States? Science 2000;290:1881-3.
17. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa Ade A, Vasconcelos AW, et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 1993;92:2626-32.
18. Murray HW, Montelibano C, Peterson R, Sypek JP. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J Infect Dis 2000;182:1497-502.
19. Spellberg B, Edwards JE, Jr. Type 1/ type 2 immunity in infectious diseases. Clin Infect Dis 2001;32:76-102.
20. Reed SG. Leishmaniasis vaccination: targeting the source of infection. J Exp Med 2001;194:F7-9.
21. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001;14:229-43.
22. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002;2: 845-58.
23. Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra. WO, Gollob KJ, Carvalho EM. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002;70:6734-40.
24. Parnpiglione S, Manson-Bahr PE, Giungi F, Giunti G, Parenti A, Canestri Trotti G. Studies on Mediterranean Leishmaniasis, Asymptomatic cases of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1974;68:447-53.
25. Anstead GM, Chandrasekar B, Zhao W, Yang J, Perez LE, Melby PC. Malnutrition alters the innate response and increases early visceralization following Leishmania donovani infection. Infect Immun 2001;69:4709-18.
26. Silva ES, Gontijo CMF, Pacheco RS, Fiuza VO, Brazil RP Visceral leishmaniasis in the metropolitan region of Belo Horizonte, State of Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 2001;96:285-91.
27. Peacock CS, Collins A, Shaw MA, Silveira F, Costa J, Coste CH, et al. Genetic epidemiology of visceral leishmaniasis in northeastern Brazil. Genet Epidemiol 2001;20:383-96.
28. Grech V Mizzi J, Mangion M, Vella C. Visceral leishmaniasis in Maltaan 18-year paediatric, population based study. Arch Dis Child 2000;82:381-5.
29. Maltezou HC, Siafas C, Mavrikou M, Spyridis P Stavrinadis C, Karpathios Th, et al. Visceral leishmaniasis during childhood in southern Greece. Clin Infect Dis 2000;31:1139-43.
30. Minodier P, Garnier JM. La leishmaniose viscerale infantile en Provence. Arch Pediatr 2000;7(Suppl. 3):572s-77s.
31. Bryceson A. Visceral leishmaniasis in India. Lancet 2000;356:1933.
32. Sundar S, Pai K, Kumar R, Pathak-Tripathi K, Gam AA, Ray M, Kenney RT. Resistance to treatment in kala-azar: speciation of isolates from northeast India. Am J Trop Med Hyg 2001;65:193-6.
33. Jeronimo SM, Teixeira MJ, De Queirzo Sousa A, Thielking P, Pearson RD, Evans TG. Natural history of Leishmania chagasi infection in northeastern Brazil: long-term follow-up. Clin Infect Dis 2000;30:608-9.
34. Abramson MA, Dietze R, Frucht DM. Schwantz R, Kenney RT. Comparison of New and Old World leishmanins in an endemic region of Brazil. Clin Infect Dis 1995,20:1292-7.
35. Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM. Pbst-kala-azar dermal leishmaniasis in the Sudan: clinical presentation ad differential diagnosis. Br J Dermatol 2000;143:136-43.
36. Zijlstra EE, el-Hassan AM, Ismael A. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1995;52:299-305.
37. Gagnaire MH, Galambrun C, Stephan JL. Haemophagocytic syndrome: a misleading complication of visceral leishmaniasis in children-a series of 12 cases. Paediatrics 2000;106:E58.
38. Prasad LS. Kala azar. Indian J Paediatr 1999;66:539-46.
39. Hepburn NC. Management of cutaneous leishmaniasis. Curr Opin Infect Dis 2001;14:151-4.
40. Da Matta VL, Hoshino-Shimizu S, Dietze R, Corbett CE. Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis. J Clin Lab Anal 2000;14:5-12.
41. Zijlstra EE, Nur Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health 2001;6:108-13.
42. Salotra P, Sreenivas G, Pogue GP, Lee N, Nakhasi HL, Ramesh V, Negi NS. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kalaazar and post-kala-azar dermal leishmaniasis. J Clin Microbiol 2001;39:849-54.
43. Spanakos G, Patsoula E, Kremastinou T, Saroglou G, Vakalis N. Development of a PCR-based method for diagnosis of Leishmania in blood samples. Mol Cell Probes 2002;16:415-20
44. Barral A, Honda E, Caldas A, Costa J, Vinhas V, Rowton ED, et al. Human immune response to sand fly salivary gland antigens: a useful epidemiological marker? Am J Trop Med Hyg 2000;62:740-5.
45. Kuyucu N, Kara C, Bakirtac A, Tezic T. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimonate. Pediatr Infect Dis J 2001;20:455-7.
46. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000;31:1104-7.
47. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001;45:2185-97.
48. Gaeta GB, Maisto A, Di Caprio D, Scalone A, Pasquale G, Felaco FM, et al. Efficacy of amphotericin-B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent patients. Scand J Infect Dis 2000;32:675-7.
49. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin-B: randomized trial. BMJ 2001;323:419-22.
50. Thakur CP. A single high dose treatment of kala-azar with AmBisome (amphotericin-B lipid complex): a pilot study. Int J Antimicrob Agent 2001;17:67-70.
51. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000;356:1565-9.
52. Valenzuela JG, Belkaid Y, Garfield MK, Mendez S, Kamhawi S, Rowton ED, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001;194:331-42.
53. Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000;63:184-8.
54. Campbell-Lendrum D, Dujardin JP, Martinez E, Feliciangeli MD, Perez JE, Silans LN, et al. Domestic and peridomestic transmission of American cutaneous leishmaniasis: changing epidemiological patterns present new control opportunities. Mem Inst Oswaldo Cruz 2001;96:159-62.
55. Schlein Y, Jacobson RL, Muller GC. Sand fly feeding on noxious plants: a potential method control of leishmaniasis. Am J Trop Med Hyg 2001;65:300-3.
56. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995;73:191-7.